Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients

Detalhes bibliográficos
Autor(a) principal: Brito, Luiz Gustavo Oliveira
Data de Publicação: 2011
Outros Autores: Schiavon, Viviane Fernandes, Andrade, Jurandyr Moreira de, Tiezzi, Daniel Guimarães, Peria, Fernanda Maris, Marana, Heitor Ricardo Cosiski
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
DOI: 10.1590/S1807-59322011000800002
Texto Completo: https://www.revistas.usp.br/clinics/article/view/19252
Resumo: BACKGROUND: Locally advanced breast cancers are more prevalent in underdeveloped countries. Targeted therapy has been improved to identify hallmarks that are specific to these subtypes of tumors. OBJECTIVES: We aimed to prospectively assess the expression of Hypoxia inducible factor-1 α and vascular endothelial growth factor-C in locally advanced breast cancer patients. METHODS: Thirty women underwent incisional biopsies for the histopathological diagnosis of breast carcinoma and participated in neoadjuvant chemotherapy. The association of Hypoxia inducible factor-1 α and vascular endothelial growth factor-C with age, tumor size, histological grade, clinical staging, hormonal and axillary status, clinical and pathological response after neoadjuvant chemotherapy, expression of estrogen and progesterone receptors, and the presence of c-erbB-2 antigen was studied. RESULTS: Hypoxia inducible factor-1 α expression and Vascular endothelial growth factor-C expression were observed in 66.7% and 63.3% of all patients, respectively, and were marginally associated with each other (p = 0.06). Among the studied variables, only positive axillary status was associated with the presence of HIF-1α (p = 0.02). Complete pathological response was significantly associated (p = 0.04) with the expression of vascular endothelial growth factor-C prior to neoadjuvant chemotherapy. CONCLUSION: We concluded that Hypoxia inducible factor-1 α was associated with a poor prognosis and that vascular endothelial growth factor-C could be used as a predictive factor in locally advanced breast cancer patients with complete pathological response after neoadjuvant chemotherapy.
id USP-19_03992cd90a423843b830bcb9ed92bbf0
oai_identifier_str oai:revistas.usp.br:article/19252
network_acronym_str USP-19
network_name_str Clinics
spelling Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients Locally advanced breast cancerHIF-1&#945VEGFAxillary lymph nodesImmunohistochemistry BACKGROUND: Locally advanced breast cancers are more prevalent in underdeveloped countries. Targeted therapy has been improved to identify hallmarks that are specific to these subtypes of tumors. OBJECTIVES: We aimed to prospectively assess the expression of Hypoxia inducible factor-1 α and vascular endothelial growth factor-C in locally advanced breast cancer patients. METHODS: Thirty women underwent incisional biopsies for the histopathological diagnosis of breast carcinoma and participated in neoadjuvant chemotherapy. The association of Hypoxia inducible factor-1 α and vascular endothelial growth factor-C with age, tumor size, histological grade, clinical staging, hormonal and axillary status, clinical and pathological response after neoadjuvant chemotherapy, expression of estrogen and progesterone receptors, and the presence of c-erbB-2 antigen was studied. RESULTS: Hypoxia inducible factor-1 α expression and Vascular endothelial growth factor-C expression were observed in 66.7% and 63.3% of all patients, respectively, and were marginally associated with each other (p = 0.06). Among the studied variables, only positive axillary status was associated with the presence of HIF-1α (p = 0.02). Complete pathological response was significantly associated (p = 0.04) with the expression of vascular endothelial growth factor-C prior to neoadjuvant chemotherapy. CONCLUSION: We concluded that Hypoxia inducible factor-1 α was associated with a poor prognosis and that vascular endothelial growth factor-C could be used as a predictive factor in locally advanced breast cancer patients with complete pathological response after neoadjuvant chemotherapy. Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2011-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/1925210.1590/S1807-59322011000800002Clinics; Vol. 66 No. 8 (2011); 1313-1320 Clinics; v. 66 n. 8 (2011); 1313-1320 Clinics; Vol. 66 Núm. 8 (2011); 1313-1320 1980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/19252/21315Brito, Luiz Gustavo OliveiraSchiavon, Viviane FernandesAndrade, Jurandyr Moreira deTiezzi, Daniel GuimarãesPeria, Fernanda MarisMarana, Heitor Ricardo Cosiskiinfo:eu-repo/semantics/openAccess2012-05-23T16:30:14Zoai:revistas.usp.br:article/19252Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-05-23T16:30:14Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients
title Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients
spellingShingle Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients
Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients
Brito, Luiz Gustavo Oliveira
Locally advanced breast cancer
HIF-1&#945
VEGF
Axillary lymph nodes
Immunohistochemistry
Brito, Luiz Gustavo Oliveira
Locally advanced breast cancer
HIF-1&#945
VEGF
Axillary lymph nodes
Immunohistochemistry
title_short Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients
title_full Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients
title_fullStr Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients
Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients
title_full_unstemmed Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients
Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients
title_sort Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients
author Brito, Luiz Gustavo Oliveira
author_facet Brito, Luiz Gustavo Oliveira
Brito, Luiz Gustavo Oliveira
Schiavon, Viviane Fernandes
Andrade, Jurandyr Moreira de
Tiezzi, Daniel Guimarães
Peria, Fernanda Maris
Marana, Heitor Ricardo Cosiski
Schiavon, Viviane Fernandes
Andrade, Jurandyr Moreira de
Tiezzi, Daniel Guimarães
Peria, Fernanda Maris
Marana, Heitor Ricardo Cosiski
author_role author
author2 Schiavon, Viviane Fernandes
Andrade, Jurandyr Moreira de
Tiezzi, Daniel Guimarães
Peria, Fernanda Maris
Marana, Heitor Ricardo Cosiski
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Brito, Luiz Gustavo Oliveira
Schiavon, Viviane Fernandes
Andrade, Jurandyr Moreira de
Tiezzi, Daniel Guimarães
Peria, Fernanda Maris
Marana, Heitor Ricardo Cosiski
dc.subject.por.fl_str_mv Locally advanced breast cancer
HIF-1&#945
VEGF
Axillary lymph nodes
Immunohistochemistry
topic Locally advanced breast cancer
HIF-1&#945
VEGF
Axillary lymph nodes
Immunohistochemistry
description BACKGROUND: Locally advanced breast cancers are more prevalent in underdeveloped countries. Targeted therapy has been improved to identify hallmarks that are specific to these subtypes of tumors. OBJECTIVES: We aimed to prospectively assess the expression of Hypoxia inducible factor-1 α and vascular endothelial growth factor-C in locally advanced breast cancer patients. METHODS: Thirty women underwent incisional biopsies for the histopathological diagnosis of breast carcinoma and participated in neoadjuvant chemotherapy. The association of Hypoxia inducible factor-1 α and vascular endothelial growth factor-C with age, tumor size, histological grade, clinical staging, hormonal and axillary status, clinical and pathological response after neoadjuvant chemotherapy, expression of estrogen and progesterone receptors, and the presence of c-erbB-2 antigen was studied. RESULTS: Hypoxia inducible factor-1 α expression and Vascular endothelial growth factor-C expression were observed in 66.7% and 63.3% of all patients, respectively, and were marginally associated with each other (p = 0.06). Among the studied variables, only positive axillary status was associated with the presence of HIF-1α (p = 0.02). Complete pathological response was significantly associated (p = 0.04) with the expression of vascular endothelial growth factor-C prior to neoadjuvant chemotherapy. CONCLUSION: We concluded that Hypoxia inducible factor-1 α was associated with a poor prognosis and that vascular endothelial growth factor-C could be used as a predictive factor in locally advanced breast cancer patients with complete pathological response after neoadjuvant chemotherapy.
publishDate 2011
dc.date.none.fl_str_mv 2011-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/19252
10.1590/S1807-59322011000800002
url https://www.revistas.usp.br/clinics/article/view/19252
identifier_str_mv 10.1590/S1807-59322011000800002
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/19252/21315
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 66 No. 8 (2011); 1313-1320
Clinics; v. 66 n. 8 (2011); 1313-1320
Clinics; Vol. 66 Núm. 8 (2011); 1313-1320
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1822178959171780608
dc.identifier.doi.none.fl_str_mv 10.1590/S1807-59322011000800002